Thasarat S Vajaranant1, Pauline M Maki2, Louis R Pasquale3, Anne Lee4, Hajwa Kim5, Mary N Haan4. 1. Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois. Electronic address: thasarat@uic.edu. 2. Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois. 3. Department of Ophthalmology, Mass Eye and Ear, Harvard Medical School, Boston, Massachusetts; Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 4. Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, California. 5. Center for Clinical and Translational Science, University of Illinois at Chicago, Chicago, Illinois.
Abstract
PURPOSE: Previous studies suggest that hormone therapy favorably affects intraocular pressure (IOP). Here, we examined the association between hormone therapy use and IOP in the context of a large randomized trial. DESIGN: Secondary data analysis from a randomized controlled trial. METHODS: We used data from the Women's Health Initiative-Sight Exam (WHISE). Women with prior hysterectomy receivedoral conjugated equine estrogen (0.625 mg/day) or placebo. Women with a uterus receivedestrogen plus progestin (medroxyprogesterone acetate 2.5 mg/day) or placebo. IOP was measured 5 years after randomization. Adjusted linear regression models were used to assess the association between hormone therapy and IOP. RESULTS: The WHISE included 1668 women in the estrogen-alone trial (aged 63-86, mean 72 years) and 2679 women in the estrogen-plus-progestin trial (aged 63-87, mean 72 years). In multivariate analyses, compared to placebo treatment, treatment with estrogen alone was associated with a 0.5 mm Hg reduction of the IOP in the right eye (95% CI: -0.8, -0.1, P = .005) and a 0.6 mm Hg (95% CI: -0.9, -0.3, P < .001) reduction of the IOP in the left eye. In the estrogen-plus-progestin trial, there was no significant difference in IOP between the treatment and placebo groups (P = .30 right eye and P = .43 left eye). CONCLUSIONS: This study represents an IOP analysis in the largest hormone trial available. Estrogen-alone therapy in postmenopausal women is associated with a small but significant IOP reduction of 0.5 mm Hg. The clinical significance of this small decrease remains to be determined.
RCT Entities:
PURPOSE: Previous studies suggest that hormone therapy favorably affects intraocular pressure (IOP). Here, we examined the association between hormone therapy use and IOP in the context of a large randomized trial. DESIGN: Secondary data analysis from a randomized controlled trial. METHODS: We used data from the Women's Health Initiative-Sight Exam (WHISE). Women with prior hysterectomy received oral conjugated equine estrogen (0.625 mg/day) or placebo. Women with a uterus received estrogen plus progestin (medroxyprogesterone acetate 2.5 mg/day) or placebo. IOP was measured 5 years after randomization. Adjusted linear regression models were used to assess the association between hormone therapy and IOP. RESULTS: The WHISE included 1668 women in the estrogen-alone trial (aged 63-86, mean 72 years) and 2679 women in the estrogen-plus-progestin trial (aged 63-87, mean 72 years). In multivariate analyses, compared to placebo treatment, treatment with estrogen alone was associated with a 0.5 mm Hg reduction of the IOP in the right eye (95% CI: -0.8, -0.1, P = .005) and a 0.6 mm Hg (95% CI: -0.9, -0.3, P < .001) reduction of the IOP in the left eye. In the estrogen-plus-progestin trial, there was no significant difference in IOP between the treatment and placebo groups (P = .30 right eye and P = .43 left eye). CONCLUSIONS: This study represents an IOP analysis in the largest hormone trial available. Estrogen-alone therapy in postmenopausal women is associated with a small but significant IOP reduction of 0.5 mm Hg. The clinical significance of this small decrease remains to be determined.
Authors: Garnet L Anderson; Marian Limacher; Annlouise R Assaf; Tamsen Bassford; Shirley A A Beresford; Henry Black; Denise Bonds; Robert Brunner; Robert Brzyski; Bette Caan; Rowan Chlebowski; David Curb; Margery Gass; Jennifer Hays; Gerardo Heiss; Susan Hendrix; Barbara V Howard; Judith Hsia; Allan Hubbell; Rebecca Jackson; Karen C Johnson; Howard Judd; Jane Morley Kotchen; Lewis Kuller; Andrea Z LaCroix; Dorothy Lane; Robert D Langer; Norman Lasser; Cora E Lewis; JoAnn Manson; Karen Margolis; Judith Ockene; Mary Jo O'Sullivan; Lawrence Phillips; Ross L Prentice; Cheryl Ritenbaugh; John Robbins; Jacques E Rossouw; Gloria Sarto; Marcia L Stefanick; Linda Van Horn; Jean Wactawski-Wende; Robert Wallace; Sylvia Wassertheil-Smoller Journal: JAMA Date: 2004-04-14 Impact factor: 56.272
Authors: Bernhard Haring; Kathleen Hovey; Mike LaMonte; Chris Andrews; Nazmus Saquib; JoAnn E Manson; Daichi Shimbo; Robert Ritch; Carlos Gustavo De Moraes; Sylvia Wassertheil-Smoller Journal: Menopause Date: 2022-05-01 Impact factor: 2.953
Authors: Andrea Elmore; William S Harris; Lina Mu; William E Brady; Kathleen M Hovey; Julie A Mares; Mark A Espeland; Mary N Haan; Amy E Millen Journal: Eur J Nutr Date: 2022-01-06 Impact factor: 5.614
Authors: Thasarat Sutabutr Vajaranant; Roberta M Ray; Louis R Pasquale; Julie A Mares; Robert Ritch; Emily W Gower; Mary N Haan; Rebecca D Jackson; Pauline M Maki Journal: Am J Ophthalmol Date: 2018-08-04 Impact factor: 5.258
Authors: Ester Reina-Torres; Michael L De Ieso; Louis R Pasquale; Michael Madekurozwa; Joseph van Batenburg-Sherwood; Darryl R Overby; W Daniel Stamer Journal: Prog Retin Eye Res Date: 2020-11-28 Impact factor: 21.198
Authors: Louis R Pasquale; Hugues Aschard; Jae H Kang; Jessica N Cooke Bailey; Sara Lindström; Daniel I Chasman; William G Christen; R Rand Allingham; Allison Ashley-Koch; Richard K Lee; Sayoko E Moroi; Murray H Brilliant; Gadi Wollstein; Joel S Schuman; John Fingert; Donald L Budenz; Tony Realini; Terry Gaasterland; Douglas Gaasterland; William K Scott; Kuldev Singh; Arthur J Sit; Robert P Igo; Yeunjoo E Song; Lisa Hark; Robert Ritch; Douglas J Rhee; Vikas Gulati; Shane Havens; Douglas Vollrath; Donald J Zack; Felipe Medeiros; Robert N Weinreb; Margaret A Pericak-Vance; Yutao Liu; Peter Kraft; Julia E Richards; Bernard A Rosner; Michael A Hauser; Jonathan L Haines; Janey L Wiggs Journal: Menopause Date: 2017-02 Impact factor: 2.953
Authors: Jessica N Cooke Bailey; Puya Gharahkhani; Jae H Kang; Mariusz Butkiewicz; David A Sullivan; Robert N Weinreb; Hugues Aschard; R Rand Allingham; Allison Ashley-Koch; Richard K Lee; Sayoko E Moroi; Murray H Brilliant; Gadi Wollstein; Joel S Schuman; John H Fingert; Donald L Budenz; Tony Realini; Terry Gaasterland; William K Scott; Kuldev Singh; Arthur J Sit; Robert P Igo; Yeunjoo E Song; Lisa Hark; Robert Ritch; Douglas J Rhee; Douglas Vollrath; Donald J Zack; Felipe Medeiros; Thasarat S Vajaranant; Daniel I Chasman; William G Christen; Margaret A Pericak-Vance; Yutao Liu; Peter Kraft; Julia E Richards; Bernard A Rosner; Michael A Hauser; Jamie E Craig; Kathryn P Burdon; Alex W Hewitt; David A Mackey; Jonathan L Haines; Stuart MacGregor; Janey L Wiggs; Louis R Pasquale Journal: Invest Ophthalmol Vis Sci Date: 2018-02-01 Impact factor: 4.799